Highest-materiality recent filing
Royalty Pharma Q2 Royalty Receipts up 14% to $768M; raises FY 2026 guidance
Q2 Royalty Receipts $768M (+14% YoY); Portfolio Receipts $773M (+6%).
Royalty Pharma announces 2026 AGM results; all director nominees elected
All 9 director nominees elected with 88.08% quorum; Pablo Legorreta received 458.2M votes for, 29.4M against.
Royalty Pharma enters new $1.8B unsecured revolver maturing 2031
New $1.8B unsecured revolving credit facility replaces existing agreement from 2021.
Royalty Pharma Q1 Portfolio Receipts +10% to $925M; raises FY 2026 guidance
Royalty Receipts grew 13% to $887M; driven by Tremfya (+79%), Voranigo (+140%), Evrysdi (+51%).
Royalty Pharma triggers $250M milestone after positive daraxonrasib Phase 3 results
Revolution Medicines' RASolute 302 trial met primary and key secondary endpoints (PFS and OS) in metastatic PDAC.
Royalty Pharma Reports Q4 and Full Year 2025 Results; Portfolio Receipts Up 18% and 16% Respectively
Portfolio Receipts reached $874M in Q4 2025 (up 18%) and $3,254M for FY 2025 (up 16%).
FDA approves Cytokinetics' MYQORZO; Royalty Pharma to receive 4.5% royalty on sales up to $5B
Royalty Pharma entitled to 4.5% royalty on MYQORZO sales up to $5B, decreasing to 1% above $5B.
Royalty Pharma CLO George Lloyd to step down; Arthur McGivern to assume role Jan 1, 2026
George W. Lloyd transitions from EVP and Chief Legal Officer effective Dec 31, 2025.
Royalty Pharma Q3 Portfolio Receipts +11% to $814M; raises FY guidance to $3,200-$3,250M
Portfolio Receipts $814M (+11% YoY); Royalty Receipts $811M (+11%). Net cash ops $703M.
Royalty Pharma prices $2B senior notes in three tranches: 2031, 2035, 2055
$600M 4.450% notes due 2031, $900M 5.200% notes due 2035, $500M 5.950% notes due 2055.
Henry Fernandez steps down as Lead Independent Director of Royalty Pharma board
Fernandez resigned effective August 13, 2025, after five years on the board.
Royalty Pharma Q2 Portfolio Receipts +20% to $727M; raises FY 2025 guidance
Portfolio Receipts $727M (+20% YoY); Royalty Receipts $672M (+11%), driven by Voranigo, Trelegy, Evrysdi, Tremfya.
Royalty Pharma appoints Carole Ho and Elizabeth Weatherman to Board of Directors
Carole Ho (CMO of Denali Therapeutics) and Elizabeth Weatherman (Special LP at Warburg Pincus) appointed effective July 17, 2025.
Royalty Pharma closes acquisition of RP LLC; $200M cash, shares, and $380M debt assumed
Paid $200M cash plus 24,530,266 non-voting Class E shares; assumed RP Management's $380M term loan.
Royalty Pharma shareholders approve internalization deal; all director nominees elected
Proposal 2 (Membership Interest Purchase Agreement internalization) approved with 440.5M For, 74K Against.
Royalty Pharma Q1 Portfolio Receipts $839M (+17% YoY); raises FY2025 guidance
Royalty Receipts grew 12% to $788M; cystic fibrosis franchise, Trelegy, Xtandi drove growth.
Royalty Pharma amends purchase agreement to issue Class B shares to sellers at closing
Amendment No. 1 adds Royalty Pharma plc as a party to the existing Purchase Agreement.
Royalty Pharma appoints Vlad Coric, M.D., to Board of Directors effective April 7, 2025.
Dr. Vlad Coric appointed to Royalty Pharma Board effective April 7, 2025.
Royalty Pharma Q4 2024: Royalty Receipts +12% to $729M; 2025 guidance $2.9B–$3.05B
Portfolio Receipts $742M in Q4 (+1% YoY); FY 2024 $2,801M (-8% due to $525M Biohaven milestones in 2023).
Royalty Pharma presents at J.P. Morgan; no financial details in filing
Presentation at 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.
Royalty Pharma to acquire external manager for ~$1.1B, announces $3B buyback
Acquires manager RP Management for ~$1.1B: $200M cash, $380M debt assumed, 24.5M RPH shares (4% of shares).
Royalty Pharma expects FY 2024 Portfolio Receipts ~$2.8B, at upper end of guidance
FY 2024 Portfolio Receipts expected ~$2,800M (upper end of $2,750-$2,800M range).
Royalty Pharma amends exchange agreement for internal EPA holdings restructuring
Amended Exchange Agreement transfers Holdings C Share from RPI EPA Holdings to RPI EPA Vehicle.
Royalty Pharma Q3 portfolio receipts up 15% to $735M; raises FY guidance to $2.75-2.8B
Royalty Receipts grew 15% to $732M; Portfolio Receipts $735M, driven by Trelegy, Evrysdi, cystic fibrosis franchise.
FDA approved KarXT (xanomeline-trospium) for adult schizophrenia; BMS to market as Cobenfy.
Royalty Pharma Q2 Portfolio Receipts $608M (+12% YoY); raises FY 2024 guidance to $2.7-2.775B
Royalty Receipts grew 11% to $605M, driven by cystic fibrosis franchise, Trelegy (+32%), Tremfya (+34%), and Evrysdi (+91%).
FDA approves Voranigo; Royalty Pharma pays $905M milestone, expects >$150M/yr royalties
FDA approved Voranigo (vorasidenib) for IDH1/2 mutant diffuse glioma on August 6, 2024.
Royalty Pharma increases Evrysdi royalty stake to 90.5% for $242M from PTC option exercise
PTC exercised option to sell half its retained Evrysdi royalty to Royalty Pharma for ~$242M upfront.
Royalty Pharma closes $1.5B senior notes offering across three tranches
Issued $500M 5.150% notes due 2029, $500M 5.400% notes due 2034, $500M 5.900% notes due 2054.
Royalty Pharma shareholders elect all eight directors at June 6 AGM; all proposals pass
All eight director nominees elected with 457M–482M For votes; broker non-votes 24.8M per nominee.
Royalty Pharma prices $1.5B senior notes offering across three tranches
Issued $500M 5.150% Senior Notes due 2029, $500M 5.400% due 2034, and $500M 5.900% due 2054.
J&J Phase 3 seltorexant meets all endpoints; Royalty Pharma holds mid-single-digit royalty
J&J's Phase 3 MDD3001 trial of seltorexant met all primary and secondary endpoints in MDD with insomnia.
Royalty Pharma Q1 Royalty Receipts +14% to $705M; FY2024 guidance reaffirmed
Portfolio Receipts of $717M, down 37% from $1,131M YoY due to $475M Biohaven milestone in Q1 2023.
Royalty Pharma Q4 Portfolio Receipts $736M (-31% YoY); FY23 $3,049M (+9%); FY24 guide $2.6-2.7B
Portfolio Receipts Q4 $736M (down 31% YoY due to prior-year accelerated Biohaven payments); FY23 $3,049M (+9%).
Royalty Pharma details royalties and funding from Novartis acquisition of MorphoSys at €68/share
Royalty Pharma holds 3% royalty on pelabresib (myelofibrosis) and tulmimetostat (EZH2 inhibitor) future sales; NDA submission expected mid-2024.
Portfolio Receipts for FY2023 expected ~$3.05B, above prior guidance of $2.95B-$3.0B; underlying growth 11% YoY.
Cytokinetics' aficamten Phase 3 success triggers $75M milestone for Royalty Pharma
Cytokinetics announced positive Phase 3 SEQUOIA-HCM results for aficamten in symptomatic obstructive HCM.
Royalty Pharma ups revolving credit facility to $1.8B, extends majority to Dec 2028
Borrowing capacity increased from $1.5B to $1.8B via Amendment No. 3.
Royalty Pharma files prospectus for 383,000 shares under equity incentive plan
Prospectus supplement covers up to 383,000 Class A ordinary shares.
Royalty Pharma Q3 2023: $637M Adj Cash Receipts (+7% YoY); raises FY23 guidance
Adjusted Cash Receipts of $637M (+7% YoY); operating cash flow $574M (+6%).
Royalty Pharma draws $350M from revolver to fund Evrysdi royalty purchase
Subsidiary borrowed $350M under $1.5B five-year unsecured revolver on Oct 18, 2023.
Royalty Pharma Q2 adj cash receipts $545M (+4%); raises 2023 guidance to $2.9-2.975B
Net cash from ops $608M (+6% YoY); Adjusted Cash Receipts $545M (+4%), Adjusted EBITDA $498M (+4%).
Royalty Pharma shareholders elect all 10 director nominees; all AGM proposals pass
All ten director nominees elected, with support ranging from 79.2% (Gregory Norden) to 99.7% (M. Germano Giuliani).
Royalty Pharma Q1 adjusted cash receipts $1,131M (+87% YoY); reaffirms FY guidance $2,850-2,950M
Adjusted Cash Receipts $1,131M, +87% YoY; underlying growth 11% ex-Zavzpret milestone and Biohaven payments.
Royalty Pharma adopts Articles amendments to enable share repurchase program
Royalty Pharma Holdings Ltd amended its Articles of Association on March 24, 2023.
Royalty Pharma receives $475M milestone from Pfizer on Zavzpret approval, raises 2023 guidance
Received $475M accelerated milestone payment from Pfizer following FDA approval of Zavzpret (zavegepant) for acute migraine.
Royalty Pharma Q4 Adj Cash Receipts up 96% YoY; guides FY23 $2.375-$2.475B excl. $475M milestone
Q4 2022 Adj Cash Receipts $1,064M (+96% YoY); FY 2022 $2,789M (+31%).
Royalty Pharma expects 2022 Adj. Cash Receipts ~$2.79B, at upper end of guidance; 31% YoY growth
2022 Adjusted Cash Receipts (non-GAAP) expected ~$2,785-2,790M, towards upper end of $2,750-2,800M guidance; 31% YoY growth.
Royalty Pharma records $273.6M impairment on gantenerumab royalty after Roche halts trials
Non-cash impairment charge of $273.6M related to gantenerumab financial royalty asset.
Net cash from operating activities $539M (+15% YoY); Adjusted Cash Flow $441M (+26% YoY).
Effective April 7, 2025, Dr. Vlad Coric was appointed to serve as a new member of the Board of Directors (the “Board”) of Royalty Pharma plc (the “Company”).
Max materiality 0.90 · Median 0.70 · Most common event earnings